DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (“MVPHS”) of $15,000,000, based on Nasdaq’s review of the ...

Core Viewpoint - iRhythm Holdings, Inc. is set to release its financial results for Q4 and the full year 2025 on February 19, 2026, with a conference call scheduled for the same day [1]. Company Overview - iRhythm is a leading digital health care company focused on creating solutions that detect, predict, and prevent disease [3]. - The company utilizes wearable biosensors and cloud-based data analytics combined with proprietary algorithms to transform data from millions of heartbeats into clinically actionable information [3]. - iRhythm aims to enhance patient care by delivering better data, insights, and health outcomes [3]. Investor Information - Interested parties can access a live and archived webcast of the upcoming conference call on the company's investor website [2]. - The investor contact for inquiries is Stephanie Zhadkevich [4].

Company Overview - Trinity Biotech plc is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [5][6] - The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments [5][6] Recent Developments - The company announced the appointment of Paul Tivnan as a Non-Executive Director on its Board of Directors [1] - Mr. Tivnan has over 25 years of senior leadership experience in finance, capital markets, and corporate governance across various sectors, including infrastructure and cleantech [2][3] - His previous roles include CFO of Deriva Energy LLC and CFO of Brookfield Renewable Ireland, where he led a successful IPO [2][3] Strategic Goals - The appointment of Mr. Tivnan is aimed at strengthening corporate governance and bringing diverse perspectives to the Board as the company pursues growth opportunities in diagnostics and wearable health technologies [3] - Trinity Biotech is focused on executing its transformation strategy and developing a range of biosensor devices, starting with a continuous glucose monitoring product [6]